Which pneumococcal vaccine is appropriate for an adult: the 20‑valent pneumococcal conjugate vaccine (PCV20) or the 21‑valent formulation?

PCV20 and PCV21 Are Both Acceptable Options for Adult Pneumococcal Vaccination

Both PCV20 (20-valent) and PCV21 (21-valent) pneumococcal conjugate vaccines are recommended as equivalent options for adults requiring pneumococcal vaccination, according to the 2024 ACIP guidelines 1. The choice between them depends primarily on local serotype epidemiology, specifically the prevalence of serotype 4 disease in your community.

Key Decision Algorithm

Step 1: Determine if Serotype 4 is Prevalent in Your Community

• If serotype 4 accounts for ≥30% of invasive pneumococcal disease (IPD) in your population: Use PCV20 (or PCV15 + PPSV23 series) instead of PCV21 1

  • This applies particularly to certain populations in the western United States, Alaska, and the Navajo Nation where high proportions of serotype 4 disease have been documented
  • PCV21 does not contain serotype 4, while PCV20 does

• If serotype 4 accounts for <30% of IPD: Either PCV20 or PCV21 is appropriate 1

Step 2: Apply Standard Vaccination Schedules

Both vaccines follow identical scheduling recommendations based on age and risk factors 1:

For adults ≥65 years with no prior pneumococcal vaccination:

• Single dose of PCV21, PCV20, or PCV15 (if PCV15 used, follow with PPSV23 ≥1 year later)

For adults 19-64 years with immunocompromising conditions, CSF leak, or cochlear implant:

• Single dose of PCV21, PCV20, or PCV15 (if PCV15 used, follow with PPSV23 ≥8 weeks later)

For adults 19-64 years with chronic medical conditions (diabetes, heart disease, lung disease, liver disease, smoking, alcoholism):

• Single dose of PCV21, PCV20, or PCV15 (if PCV15 used, follow with PPSV23 ≥1 year later)

Important Nuances

Serotype Coverage Differences

PCV21 contains eight unique serotypes not found in PCV20, PCV15, or PPSV23, providing broader coverage against emerging strains 1. However, it lacks serotype 4, which remains clinically important in certain populations. This trade-off means:

• PCV21 covers 83-88% of IPD in US adults overall 2
• In populations with high serotype 4 prevalence, PCV20 provides more relevant local protection 1

Economic Considerations

Recent modeling suggests PCV21 may offer favorable cost-effectiveness compared to PCV20 in most scenarios 3, 2:

• PCV21 remains cost-saving when serotype 4 accounts for ≤27% (ages 19-49) or ≤36% (ages 50-64) of IPD 2
• When serotype 4 prevalence exceeds these thresholds, PCV20 becomes more economically favorable

Previously Vaccinated Adults

For adults who received PCV13 and PPSV23 at age ≥65 years, shared clinical decision-making is recommended regarding whether to administer PCV21 or PCV20 1. If given, wait ≥5 years after the last pneumococcal vaccine dose.

Common Pitfalls to Avoid

1. Don't assume PCV21 is automatically "better" because it has more serotypes - the absence of serotype 4 is clinically significant in certain populations

2. Don't mix vaccine products unnecessarily - if starting with PCV20 or PCV21, the series is complete and no additional doses are needed (unlike PCV15 which requires PPSV23 follow-up) 1

3. Don't forget minimum intervals - when switching between vaccine types, respect the ≥1 year interval (or ≥5 years for certain scenarios) 1

4. Check local epidemiology - contact your state health department or review CDC's Active Bacterial Core surveillance data to determine local serotype 4 prevalence before defaulting to PCV21

Practical Implementation

In real-world practice, if you don't have specific data showing ≥30% serotype 4 prevalence in your community, either PCV20 or PCV21 is appropriate. Most clinicians can use whichever vaccine is readily available at their practice. For populations known to have elevated serotype 4 disease (certain Native American communities, parts of the western US), specifically choose PCV20 or the PCV15 + PPSV23 series 1.